Press Releases
Jan. 29, 2020 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2019
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3 ™?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced it has filed its unaudited… Read more »
Bioasis Technologies Inc. Announces Warrant Extension and Repricing
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative… Read more »
Jan. 6, 2020 Bioasis Announces Shares for Debt Transaction
Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that… Read more »
Bioasis to Present at Upcoming Industry Conferences
Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced… Read more »
Dec. 23, 2019 Bioasis Completes Bridge Financing Transaction
This News Release Is Intended for Distribution in Canada Only and Is Not Intended for Distribution to United States Newswire Services or Dissemination in the United States GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of… Read more »
Dec. 16, 2019 Bioasis Announces Bridge Financing
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of… Read more »
Dec. 5, 2019 Bioasis Announces Annual General Meeting Results
GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »
Dec. 4, 2019 Bioasis Appoints Consultant Chief Medical Officer and Nominates Medical Oncology Advisory Board
Dr. John DeGroot, Dr. Hope Rugo and Dr. Javier Cortés Join Medical Oncology Advisory Board GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in… Read more »
Nov. 27, 2019 Bioasis to Host Annual General Meeting Webcast on December 5, 2019
GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »
Nov. 25, 2019 Bioasis Announces Director Resignation
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and… Read more »